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ABSTRACT: Rho family GTPases modulate actin cytoskeleton
dynamics by signaling through multiple effectors, including the
p21-activated kinases (PAKs). The intestinal parasite Entamoeba
histolytica expresses ∼20 Rho family GTPases and seven isoforms
of PAK, two of which have been implicated in pathogenesis-
related processes such as amoebic motility and invasion and host
cell phagocytosis. Here, we describe two previously unstudied
PAK isoforms, EhPAK4 and EhPAK5, as highly specific effectors
of EhRacC. A structural model based on 2.35 Å X-ray
crystallographic data of a complex between EhRacCQ65L·GTP
and the EhPAK4 p21 binding domain (PBD) reveals a fairly well-
conserved Rho/effector interface despite deviation of the PBD α-
helix. A structural comparison with EhRho1 in complex with
EhFormin1 suggests likely determinants of Rho family GTPase
signaling specificity in E. histolytica. These findings suggest a high degree of Rho family GTPase diversity and specificity in the
single-cell parasite E. histolytica. Because PAKs regulate pathogenesis-related processes in E. histolytica, they may be valid
pharmacologic targets for anti-amoebiasis drugs.
Rho family GTPases are master regulators of multiple keycellular processes such as cell division, transcription, and,
most prominently, dynamic reorganization of the actin
cytoskeleton.1,2 Inactive, GDP-bound Rho GTPases are
activated by guanine nucleotide exchange factors (GEFs) that
promote release of GDP and subsequent binding of GTP.3,4
Rho GTPases undergo a conformational change dominated by
two mobile switch regions upon binding GTP, allowing
engagement of downstream effectors.2 Among the established
Rho family GTPase effectors are the p21-activated kinases, or
PAKs, that contain an N-terminal regulatory domain with a p21
binding domain (PBD) and a C-terminal kinase domain.5 The
six mammalian PAKs can be classified into two groups with
distinct structural features and mechanisms of activation.6 The
regulatory domains of group I PAKs (PAK1−3) contain an
autoinhibitory domain (AID) that partially overlaps with the
PBD.5 The C-terminal portion of the AID, termed the kinase
inhibitory domain (KI), lies in the catalytic cleft of the kinase
domain, preventing efficient phosphorylation of PAK substrates
in the absence of active Rho GTPase.7 Activation of the best-
studied group member, PAK1, occurs through a multistep
process involving binding of Cdc42 or Rac to the PBD,
reorganization of the KI, and phosphorylation of the kinase
domain activation loop.7 Once activated, PAK1 phosphorylates
numerous signaling proteins, including β-catenin and the
mitogen-activated protein kinase kinase MEK1.8,9 In contrast,
early studies of group II PAKs detected higher basal levels of
kinase activity that were not dramatically altered upon
interaction with Cdc42 or Rac, suggesting Rho family
GTPase-dependent localization of PAK, rather than auto-
inhibition, as the primary mode of group II PAK signaling.5
More recent studies suggest the presence of a structurally
distinct but functionally similar autoinhibitory segment in
group II PAKs.6 Although activation loop phosphorylation is
constitutive, binding of Cdc42 or Rac to the PBD is thought to
be required to displace the autoinhibitory segment and
promote full activation of group II PAKs.6 Human PAKs
have emerged as drug targets, particularly in specific
cancers.10,11 For instance, the small molecule IPA-3 was
recently identified as a covalent modifier and inhibitor of
PAK1 activation.12,13
The intestinal parasite Entamoeba histolytica is the causative
agent of amoebic colitis and systemic amoebiasis.14 Encysted E.
histolytica is spread primarily through contaminated food and
water sources among poor populations of developing countries,
although outbreaks among travelers and susceptible popula-
tions occur in the United States.14 E. histolytica cysts cycle to
the trophozoite form in the human intestine and may give rise
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to local destruction of the intestinal mucosa (amoebic colitis)
or more rarely may enter the bloodstream, leading to systemic
amoebiasis characterized by liver, lung, and brain abscesses.15
The pathogenesis of E. histolytica infection depends on a highly
dynamic, actin-rich trophozoite cytoskeleton.16 Single-cell
trophozoites express ∼20 Rho family GTPases and downstream
signaling effectors important for coordination of actin
cytoskeletal rearrangement in pathogenesis-related processes,
including migration and chemotaxis, adherence to intestinal
epithelium, and host cell killing and phagocytosis (reviewed in
ref 17). For instance, expression of constitutively active EhRacA
or EhRacG in E. histolytica trophozoites alters phagocytosis and
surface receptor capping,18,19 while EhRho1 engages a
diaphanous-related formin effector, EhFormin1, to directly
modulate actin polymerization.20,21 EhRacC directly interacts
with the heterotrimeric G protein effector EhRGS-RhoGEF
and, together with EhGα1, promotes Rac GTPase activation in
cells.22
Six PBD-containing kinases related to mammalian PAKs are
also encoded by the E. histolytica genome.17,23 An additional
protein, EhPAK (also called EhPAK1), does not contain a
conserved PBD but was found to bind human Rac1 at its N-
terminus.24 EhPAK1 localizes to the leading edge of migrating
trophozoites and is implicated in amoeboid migration, polarity,
and human red blood cell phagocytosis.24 EhPAK2 has a role in
collagen matrix invasion, and its PBD selectively engages
activated EhRacA.17,23 A third studied PAK, EhPAK3,
autophosphorylates in vivo and displays in vitro kinase activity
in the absence of small GTPases.25 Thus, E. histolytica PAKs
regulate pathogenesis-related processes, particularly trophozoite
migration and extracellular matrix invasion. However, the
relationship of E. histolytica PAK isoforms to mammalian PAKs
remains unclear; specifically, it is not known how their
activation mechanisms are related to mammalian group I and
group II modes of autoinhibition. The degree of Rho family
GTPase/PAK signaling specificity in E. histolytica is also an
unresolved question, given the apparent simultaneous ex-
pression of ∼20 Rho family GTPases and up to seven PAKs in
a single-cell organism. Here, we quantify the GTPase binding
selectivity of two previously unstudied E. histolytica PAKs and
determine the structural relationship of the EhRacC/EhPAK4
PBD interface to mammalian homologues.
■ EXPERIMENTAL PROCEDURES
Cloning and Protein Purification. Genomic DNA was
isolated from the virulent HM-1:IMSS strain of E. histolytica
using a DNeasy Blood and Tissue Kit (Qiagen). EhRho1,
EhRacC, EhRacD, and EhRacG were cloned from genomic
DNA by polymerase chain reaction (PCR) amplification as
hexahistidine-tagged open reading frame fusions, expressed in
B834 Escherichia coli, purified by nickel affinity and gel filtration
chromatography, and loaded with nucleotide as described
previously.21 For EhRacC (AmoebaDB accession number
EHI_070730) used in crystallographic experiments, the flexible
C-terminal tail that includes the CaaX prenylation motif (11
residues) was excluded, and a glutamine (Q65) required for
GTPase activity was mutated to leucine using the two-PCR
method.26 The EhRacCQ65L N-terminal hexahistidine tag was
removed with tobacco etch virus (TEV) prior to NTA affinity
chromatography and gel filtration, as described previously for
EhRho1.20 Open reading frames of the isolated p21 binding
domains (PBDs) of EhPAK4 (EHI_152540, amino acids 12−
78) and EhPAK5 (EHI_043140, amino acids 105−161) were
amplified via PCR from genomic DNA and subcloned as
hexahistidine fusions into a pET vector-based ligation-
independent cloning vector, pLIC-His, as described previ-
ously.20 The following PCR primer sequences were used:
EhPAK4, 5′-GAACTTATCATTTCTGATC-3′ and 5′-TTAT-
GTTCTATTTCCATTATC-3′; and EhPAK5, 5′-GATATTA-
GTGAACCAACAG-3′ and 5′-TTATTGTGTGAATTCTAA-
TAC-3′. For each E. histolytica PAK, B834 Es. coli cells were
grown to an OD600 of 0.8 at 37 °C and expression was induced
with 500 mM isopropyl β-D-thiogalactopyranoside (IPTG) for
14−16 h at 20 °C. Pelleted bacterial cells were resuspended in
N1 buffer containing 30 mM HEPES (pH 8.0), 250 mM NaCl,
and 30 mM imidazole and lysed by high-pressure homoge-
nization with an Emulsiflex (Avestin, Ottawa, ON). Cellular
lysates were cleared by centrifugation at 100000g for 1 h at 4
°C, and the supernatant was applied to a nickel-nitrilotriacetic
acid (NTA) FPLC column (GE Healthcare), washed
extensively with N1, and eluted in N1 buffer with 300 mM
imidzaole. For proteins used in biochemical experiments, eluted
protein was pooled and resolved using a size exclusion column
(HiLoad 16/60 Superdex 200, GE Healthcare) in S200 buffer
containing 50 mM HEPES (pH 7.5), 100 mM NaCl, and 5 mM
DTT. For proteins used in crystallographic studies, protein
eluted from the NTA column was pooled and dialyzed into
imidazole-free N1 supplemented with 5 mM DTT overnight at
4 °C in the presence of His6-tobacco etch virus (TEV) protease
to cleave the N-terminal affinity tag. The dialysate was then
passed over a second NTA column to remove TEV protease
and uncleaved protein, followed by resolution by size exclusion
in S200 buffer. Proteins were concentrated to 0.25−2 mM and
snap-frozen in a dry ice/ethanol bath for storage at −80 °C.
The protein concentration was determined by A280 measure-
ments upon denaturation in 8 M guanidine hydrochloride,
based on predicted extinction coefficients for each protein.
Crystallization and Determination of the Structure of
the EhRacCQ65L·GTP/EhPAK4 PBD Complex. A stable 1:1
complex of EhRacCQ65L·GTP and EhPAK4 PBD was
assembled over a gel filtration column. Crystals were obtained
by vapor diffusion from hanging drops at 18 °C by mixing the
EhRacCQ65L·GTP/EhPAK4 complex (13 mg/mL) in a 1:1 ratio
with a crystallization solution containing 22% (w/v) PEG 4000,
200 mM MgCl2, and 100 mM MES (pH 6.5). Crystals grew to
∼300 μm × 200 μm × 100 μm over 5−7 days, exhibiting the
symmetry of space group P21 (a = 49.3 Å, b = 212.0 Å, c = 49.8
Å, α = γ = 90°, and β = 102.8°) and containing four
EhRacCQ65L·GTP/EhPAK4 dimers in the asymmetric unit
(Table 1). For the collection of data at 100 K, crystals were
serially transferred for ∼1 min into a crystallization solution
supplemented with 30% (v/v) glycerol in 10% increments and
plunged into liquid nitrogen. Native data sets were collected at
the GM/CA-CAT 23-ID-B beamline at the Advanced Photon
Source (Argonne National Laboratory, Argonne, IL). Data were
processed using HKL2000.27 A structural model of human
Rac1 from X-ray crystallography [Protein Data Bank (PDB)
entry 3TH5], modified to exclude bound nucleotide and
magnesium, served as a molecular replacement search model
using PHENIX AutoMR.28 Upon molecular replacement,
strong electron density was observed for GTP and magnesium,
as well as the secondary structural elements of the EhPAK4
PBD. The EhPAK4 structural model was manually built with
alternating iterations of refinement. Refinement was conducted
using phenix.refine,28 interspersed with manual revisions of the
model using Coot.29 Refinement consisted of conjugate
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gradient minimization and calculation of individual anisotropic
displacement and translation/libration/screw (TLS) parame-
ters.30 The current model contains four EhRacCQ65L·GTP/
EhPAK4 PBD dimers in the asymmetric unit. EhRacC residues
1−4 and 182 in chain A, residues 1−4 in chain B, residues 1
and 2 in chain C, and residues 1 and 2 in chain D could not be
located in the electron density. EhPAK4 residues 52−78 in
chain E, residues 1 and 51−78 in chain F, and residues 52−78
in chains G and H could not be located in the electron density.
Ramachandran plot analysis indicated 98.5% favored, 1.5%
allowed, and 0% disallowed residues.
Surface Plasmon Resonance (SPR) Assays. SPR-based
measurements of protein−protein interactions were performed
on a Biacore 3000 (GE Healthcare) and a Bio-Rad ProteOn
XPR36 instrument, essentially as described previously.20 Briefly,
purified His6-EhPAK4 PBD and His6-EhPAK5 PBD proteins
were separately immobilized on an NTA biosensor chip using
covalent capture coupling.31 EhRacC, EhRacCQ65L, EhRacD,
EhRacG, or EhRho1 was injected in 30−100 μL volumes at
increasing concentrations. Experiments were performed in a
running buffer containing 50 mM HEPES (pH 7.4), 150 mM
NaCl, 0.05% NP-40 alternative (Calbiochem), 50 μM EDTA,
and 1 mM MgCl2. Background changes in refractive index upon
injection of samples were subtracted from all curves using
BIAevaluation version 3.0 (GE Healthcare) or ProteOn
Manager (Bio-Rad). Equilibrium binding analyses were
conducted as previously described32 using GraphPad Prism
version 5.0 to determine binding affinities. Kinetic analyses
were performed on triplicate Rho GTPase injections as
previously described.33
■ RESULTS
E. histolytica PAK Genes Resemble Mammalian Group
I PAKs. The E. histolytica genome encodes seven putative p21-
activated kinases (PAKs),34 three of which have been previously
characterized.23−25,35 Although three E. histolytica PAKs possess
N-terminal PH domains not seen in mammalian PAKs,23 the
p21 binding domains (PBDs) in E. histolytica are significantly
similar with those of mammalian PAKs (Figure 1). The protein
sequences immediately C-terminal to the PBDs in all E.
histolytica PAKs resemble the mammalian group I PAK
autoinhibitory domains (AIDs), distinct from the group II
PAKs (Figure 1B).5 The average level of sequence identity of
EhPAK4 was 52% compared to human group I PAKs and 37%
compared to human group II PAKs (Figure S1 of the
Supporting Information). Although this similarity of the AIDs
suggests a shared evolutionary origin and possibly a shared
autoinhibitory mechanism with mammalian group I PAKs,
sequence similarity breaks sharply prior to the C-terminal
portion of the AID, termed the kinase inhibitory domain (KI)
(Figure 1B). In human PAK1, this segment is known to directly
inhibit the kinase active site, with a particularly important role
for Lys141.7 The absence of a clear KI counterpart in the E.
histolytica PAKs suggests either a lack of autoinhibition or an
autoinhibitory mechanism different from that of mammalian
homologues.
EhRacC Selectively Engages Two Putative PAK
Effectors. To further investigate the signaling specificity
among the ∼20 Rho family GTPases expressed in E. histolytica
and their effectors, the PBDs from two previously uncharac-
terized PAKs, EhPAK4 and EhPAK5, were cloned from
genomic DNA, expressed and purified from Es. coli, and
immobilized for surface plasmon resonance binding experi-
ments. Of four activated Rho GTPases tested, only a GTPase-
deficient EhRacC mutant (Q65L) exhibited specific binding to
both EhPAK4 and EhPAK5 (Figure 2). Equilibrium binding
analyses revealed affinity constants (KD) of 170 ± 30 nM and
1.9 ± 0.2 μM for EhPAK4 and EhPAK5 PBDs, respectively, as
well as a high degree of nucleotide state selective binding to
EhRacC, typical of Rho GTPase/effector interactions. Kinetic
analyses of both EhRacC/PAK interactions using triplicate
analyte injections indicated an ∼2.6-fold faster rate of EhRacC
association (kon) and an ∼3.3-fold slower rate of EhRacC
dissociation (koff) for EhPAK4 than for EhPAK5, consistent
with an order of magnitude difference in binding affinity
(Figure 2). The sequence diversity of the EhPAK PBDs, in
contrast to the closely related human PAK PBDs, likely allows
for interaction with a larger number of Rho family GTPases in
E. histolytica (Figure 1B); e.g., EhPAK2 engages activated
EhRacA,23 while EhPAK4 and -5 each interact with activated
EhRacC. In support of this hypothesis, sequence identities of E.
histolytica and human PAK PBDs were calculated (Figure S1 of
the Supporting Information). While human group I and group
II PAKs each share >70% PBD sequence identity, all E.
histolytica PAK PBD pairs exhibit <70% identity, with the
exception of EhPAK2 and EhPAK5 (76% identity). The E.
histolytica Rho GTPases are similarly diverse, with only four
pairs being >70% identical (Figure S1 of the Supporting
Information). Although EhPAK4 and EhPAK5 differ substan-
tially, in that EhPAK5 possesses an N-terminal PH domain and
the sequences of the kinase domains are only 56% similar
Table 1. Data Collection and Refinement Statistics for




a, b, c (Å) 49.32, 211.96, 49.78
α, β, γ (deg) 90.0, 102.85, 90
wavelength (Å) 1.000
resolution (Å) 46.9−2.35 (2.37−2.35)
no. of unique reflections 36818 (910)
Rmerge (%) 6.7 (68.7)
b
I/σI 34.7 (2.2)
completeness (%) 87.0 (85.0)
redundancy 5.0 (5.3)
Wilson B factor (Å2) 48.5
Refinementa
resolution (Å) 46.9−2.35 (2.39−2.35)
no. of reflections 36744 (1754)










bond lengths (Å) 0.013
bond angles (deg) 1.277
aValues in parentheses are for the highest-resolution shell. bAll data
were collected from a single crystal.
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(compared to ∼98% similar among human group I PAK kinase
domains), their respective PBDs are more closely related (69%
similar), consistent with our observation of both E. histolytica
PAKs engaging EhRacC.
A Crystal Structure of Activated EhRacC in Complex
with the EhPAK4 PBD. A number of functional studies of
PAKs in E. histolytica have revealed their importance for
pathogenesis-related processes;23−25,35 however, no structural
information had yet emerged. We sought to elucidate
determinants of Rho/PAK specificity in E. histolytica and to
compare this GTPase/effector interface with those of well-
characterized human homologues. Purified EhRacCQ65L·GTP
and EhPAK4 PBD were assembled into a stable 1:1 complex via
gel filtration and crystallized. A structural model was obtained
from diffraction data extending to 2.35 Å resolution by
molecular replacement using human Rac1 as a search model
(PDB entry 3TH5). Strong electron density arising from the
EhPAK4 PBD (omit map shown in Figure 3) allowed manual
building of a structural model. The overall structure of EhRacC
is highly similar to that of mammalian Rho family GTPases; a
DALI search36 revealed a 0.6 Å Cα root-mean-square deviation
(rmsd) compared to human Rac3 in complex with PAK4 (PDB
entry 2OV2). EhRacC also resembles the only other E.
histolytica Rho family GTPase of known structure, EhRho1
(PDB entry 3REG20), with an rmsd of 0.6 Å. In contrast with
EhRho1,20 however, EhRacC possesses the signature “Rho
insert” helix (Figure 3A) and retains nucleotide-interacting
residues that are highly similar to those of mammalian Rho
GTPases (Figure 1A). The EhPAK4 PBD structure consists of
a β-hairpin followed by a single α-helix, a motif conserved
among the PBDs of human PAKs and WASP.37,38
Overall, EhRacC/EhPAK4 interactions bury ∼1150 Å2 of
surface area. The first β-strand of the EhPAK4 PBD extends the
six-stranded β-sheet of EhRacC (Figure 3A). In addition to the
typical β-sheet backbone interactions, a number of EhPAK4
side chains contribute to a predominantly hydrophobic
interface with EhRacC. Leu13 and Ile15 of the EhPAK4 N-
terminal extension interact with EhRacC residues Val177 and
Leu181 and the hydrophobic portion of Lys178 on helix α5.
The EhPAK4 Pro18 residue is universally conserved among
PAK PBDs except EhPAK7 (Figure 1B) and occupies a
position very similar to that of mammalian PBDs, forming
extensive hydrophobic contacts with the aromatic ring of Tyr27
on helix α1 as well as Val46 and Leu48 on strand β2 of EhRacC
(Figure 3B). Within the first β-strand of the EhPAK4 PBD,
Phe21 makes extensive hydrophobic interactions with EhRacC
Tyr47, Ile35, and Ile29. Significant polar interactions also
contribute to the EhRacC/EhPAK4 interface in this region. For
instance, EhPAK4 residues Gln23 and His26 are within
hydrogen bonding distance of EhRacC Asp42. Arg30 in switch
1 of EhRacC likely forms a salt bridge with Asp17 of EhPAK4
(Figure 3B). This contact likely contributes to Rho/effector
specificity, because other E. histolytica Rho family GTPases lack
a basic residue in the position corresponding to Arg30 (Figure
Figure 1. Sequence comparison of E. histolytica Rho family GTPases and PAKs. (A) Nineteen E. histolytica Rho family GTPases with microarray
evidence of transcription20 are aligned with human homologues. The indicated contacts and secondary structure elements are derived from the
crystal structure of the EhRacCQ65L·GTP/EhPAK4 PBD complex presented in this study. EhRacC/EhPAK4 contacts, denoted by gray squares, were
defined as coordinates within 1 Å of the binding partner. Increasingly dark shading reflects a higher level of sequence identity. (B) Five putative E.
histolytica p21-activated kinases (PAKs) are aligned with human group I (PAK1−3) and group II (PAK 4−6) PAKs. The indicated contacts and
secondary structure are derived from the crystal structure of the EhRacCQ65L·GTP/EhPAK4 complex, while the p21 binding domain (PBD),
autoinhibitory domain (AID), kinase inhibitory segment (KI), and kinase domain all reflect human PAK1.7 AmoebaDB accession numbers are
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1A). Additionally, no other Rho GTPases other than
EHI_153460 have a hydrophobic residue in the preceding
position (Ile29) and thus likely do not interact optimally with
Phe21 of EhPAK4.
The EhPAK4 β-hairpin turn region and the α-helix give rise
to a hydrophobic patch that interacts with switch 2 and the C-
terminal portion of switch 1 in EhRacC (Figure 3B).
Participating residues are Val27, Leu29, Leu34, Leu45, and
Ile46 on EhPAK4 and Val40, Phe41, Tyr68, Leu71, and Leu73
on EhRacC. The latter five switch region residues are very well
conserved across E. histolytica Rho family GTPases (Figure 1A)
and, in the case of EhRho1, were seen to make a similar key
hydrophobic interface with the GTPase binding domain
(GBD) of EhFormin1.21 Thus, this conserved hydrophobic
face may contribute universally to E. histolytica Rho/effector
interfaces, while specificity is likely dictated by additional
interactions.
Structural Diversity of Rho Family GTPase and PBD
Interactions. We next sought to compare the EhRacC/
EhPAK4 PBD structure with those of similar mammalian Rho/
PBD complexes. Structures of human Cdc42 in complex with
the PBDs of Wiskott-Aldrich syndrome protein (WASP) (PDB
entry 1CEE37) or activated Cdc42 kinase (ACK) (PDB entry
1CF439) exhibit a similar interface along strand β2 of Cdc42, as
well as contacts at both switch regions (Figure 4). However, the
C-terminal portions of the PBDs adopt a structure more
extended than that of the EhPAK4 PBD, with ACK lacking
clear secondary structure in this region and meandering to the
opposite face of switch 2 compared with other Rho/PBD
structures. Among the available structures of mammalian Rho
family GTPases in complex with PBDs from PAKs, the majority
of PAK PBDs adopt a secondary structure, including a β-hairpin
and a single α-helix, clearly similar to that of EhRacC/EhPAK4
(Figure 4). Examples shown in Figure 4 include the group I
PAK1 PBD in complex with Cdc42 (PDB entry 1E0A38) and
the group II Cdc42/PAK6 complex (PDB entry 2ODB).
However, PAK PBD conformations with a more extended C-
terminus lacking the β-hairpin have been observed, as in
another NMR structure of Cdc42/PAK1 (PDB entry 1EES40),
possibly explained by the use of a different PAK PBD peptide.
The EhPAK4 PBD differs from each of the mammalian PBDs
of known structure in that its C-terminal α-helix lies
approximately perpendicular to the β-hairpin strands. In
contrast, the α-helices of mammalian PAK PBDs lie
approximately parallel to the β-hairpin strands (Figure 4).
The ∼90° rotated α-helix of EhPAK4 has a distinct mode of
interaction with switch 2 of its Rho GTPase partner. This
distinct structural relationship of the β-hairpin and α-helix may
be conserved among E. histolytica PAKs, as the linkers between
these two secondary structure elements are well-conserved,
including a dual-proline motif, and switch 2-contacting residues
in the α-helix are also well-conserved (Figure 1B). However,
the disposition of the EhPAK4 PBD α-helix is likely influenced
by an extensive crystal contact interface (buried surface area of
Figure 2. EhPAK4 and EhPAK5 selectively engage activated EhRacC. The isolated PBDs from EhPAK4 and EhPAK5 were immobilized and
interactions with four E. histolytica Rho family GTPases quantified using surface plasmon resonance (SPR). Rho GTPases were maintained in the
activated conformation by being loaded with nonhydrolyzable GTP analogues or, in the case of EhRacC, by mutation of a conserved glutamine
(Q65L) required for GTPase activity. Both E. histolytica PAKs were found to selectively bind activated EhRacC with high affinity, typical of Rho/
effector interactions. Equilibrium binding analyses were performed with active, GTP-bound and inactive, GDP-bound EhRacC. Kinetic parameters of
binding were derived from triplicate injections of 3 μM EhRacC. kon was derived from the equation kon = (kobs − koff)/[analyte] and an affinity
constant calculated with the equation KD = koff/kon.
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∼9300 Å2) with an EhRacC/EhPAK4 complex in the
neighboring asymmetric unit (Figure 5). The two EhPAK4 α-
helices at this interface lie approximately antiparallel to one
another, with the tandem basic and acidic residues Arg42 and
Glu43 complementing one another (Figure 5). The EhPAK4 α-
helices and the two switch 2 regions of the symmetry-related
EhRacC molecules also form a hydrophobic interface. Each of
the four EhRacC/EhPAK4 complexes in the asymmetric unit
makes similar contacts with neighboring dimers. However,
there is currently no evidence supporting formation of
tetrameric EhRacC/EhPAK4 in solution; e.g., the migration
of EhRacC/EhPAK4 upon gel filtration chromatography was
consistent with a 1:1 rather than a 2:2 complex. To assess
possible effects of the observed crystallographic dimerization on
the EhRacC/EhPAK4 complex in solution, we compared the
affinity of wild-type EhPAK4 and charge reversal mutant
EhPAK4(R42D) for EhRacC·GTP using SPR (Figure 5C).
There was no significant difference in affinity with parallel
equilibrium binding analyses.
■ DISCUSSION
Simultaneous expression of ∼20 Rho family GTPase genes in
the single-cell parasite E. histolytica suggests the importance of
Rho signaling for trophozoite biology and pathogenesis,17 as
well as likely highly specific signaling to downstream effectors.
Studies of Rho GTPase signaling specificity have so far
supported this hypothesis. For instance, the diaphanous-related
formin EhFormin1 engages EhRho1 to the exclusion of
numerous other Rho family GTPases,21 EhPAK2 interacts
with EhRacA but not EhRho1,23 and the current study reveals
EhPAK4 and EhPAK5 are highly selective for EhRacC. A
comparison of the EhRacC/EhPAK4 PBD structure with that
of EhRho1/EhFormin121 revealed a primary hydrophobic
interface involving highly conserved residues in the Rho family
GTPase switch regions. The specificity of Rho/effector
interactions is likely determined by secondary interfaces, such
as those involving less well-conserved regions in strand β2 and
helices α1 and α5 in EhRacC or helix α3 in EhRho1.21
The majority of EhPAK4 PBD residues with side chains
contributing to the EhRacC interface are well-conserved in
EhPAK5, consistent with shared specificity for a single Rho
GTPase. Although the sequences of the PBDs and isolated Rac
interface residues are 69 and 62% identical, respectively, the
observed differences are not expected to prohibit binding to
EhRacC. For instance, Asp17 of EhPAK4 forms a salt bridge
with Arg30 of EhRacC (Figure 3B); a glutamate residue of
EhPAK5 in the corresponding position likely fulfills a similar
function. Phe21 of EhPAK4 (Figure 3B) and a tyrosine of
EhPAK5 likewise are probably interchangeable in contributing
to a hydrophobic EhRacC interface. The greater affinity of
EhRacC for EhPAK4 than for EhPAK5 may be explained by
more subtle variation at the Rac/PAK interface. Gln23 of
EhPAK4 is within hydrogen bonding distance of Asp42 and
Tyr44 of EhRacC (Figure 3B), an interaction that may be less
optimally accomplished by a corresponding histidine in
EhPAK5. Ala48 of EhPAK4 lies at a hydrophobic interface
Figure 3. Structural analysis of the interface between EhRacCQ65L·GTP and the PBD of EhPAK4. (A) A complex between EhRacC (green) in its
activated conformation and the isolated PBD of EhPAK4 (red) was crystallized and its structure determined to 2.35 Å resolution. The β-sheet central
to the typical G domain fold of EhRacC is extended by association with a β-hairpin in the EhPAK4 PBD. (B and C) The EhRacC/PAK4 interface
exhibits typical β-sheet backbone interactions, as well as hydrophobic interfaces involving the EhRacC α1, α5, and switch 2 (sw2) helices, switch 1
(sw1), and strand β2. Key polar interactions also likely contribute to binding affinity, e.g., a salt bridge between EhRacC Arg30 and EhPAK4 Asp17.
The electron density represents a simulated annealing omit map calculated in the absence of the EhPAK4 model and contoured to 2.5σ.
Biochemistry Article
DOI: 10.1021/bi501226f
Biochemistry 2015, 54, 404−412
409
with EhRacC (Figure 3C), and the crystal structure model
would not accommodate the larger corresponding EhPAK5
cysteine residue, suggesting structural differences in this
peripheral aspect of the Rac/PAK interface.
Despite a high degree of selectivity among studied E.
histolytica effectors for their Rho GTPase partners, EhRacC has
emerged as being capable of engaging a plurality of effectors. In
addition to EhPAK4 and EhPAK5, activated EhRacC directly
engages the heterotrimeric G protein effector EhRGS-RhoGEF
and cooperates with EhGα1 to promote downstream Rac
activation.22 EhRacC may serve as a node for multiple
downstream signaling pathways in E. histolytica.
Three previously described PAKs in E. histolytica have been
implicated in major pathogenesis-related cellular processes,
including amoebic migration, polarity, phagocytosis, and
collagen matrix invasion.23,24 Further experimentation is
needed to assess biological functions of the EhRacC effectors
EhPAK4 and EhPAK5. These Rho family GTPase signaling
pathways may provide feasible targets for pharmacological
manipulation, given previous success with mammalian PAK
inhibitors.12,41 Specific targeting of E. histolytica PAKs,
Figure 4. Structural diversity of Rho family GTPase and PBD
interactions. The structure of the EhRacC/EhPAK4 PBD complex
exhibits similarity to structures of human Cdc42 in complex with
multiple PBD-containing effectors (Hs PAK1, PDB entry 1E0A;38 Hs
PAK6, PDB entry 2ODB; Hs WASP, PDB entry 1CEE;37 Hs ACK,
PDB entry 1CF439). The N-terminus of each PBD extends along
strand β2 of its GTPase binding partner, often also contacting helix α5
at the C-terminus of each G domain. The C-termini of PBDs are more
structurally diverse, with the PAK-derived PBDs typically forming a β-
hairpin followed by an α-helix. In contrast, the PBDs of WASP and
ACK display more extended C-termini with distinctive Cdc42
interfaces. Although the EhPAK4 PBD is clearly structurally similar
to mammalian PAKs, its α-helix adopts a unique orientation, being
approximately perpendicular to the β-hairpin strands rather than
parallel to them, as seen in mammalian homologues. However, the
disposition of the EhPAK4 PBD α-helix may be influenced by crystal
contacts (Figure 5).
Figure 5. Crystal contacts at the EhPAK4 α-helix and switch 2 of
EhRacC. (A) One of four EhRacC/EhPAK4 dimers in the asymmetric
unit is shown making contacts with a symmetry-related dimer
(EhRacCsym/EhPAK4sym). (B) The α-helices of the PBDs lie in an
antiparallel orientation and make complementary ionic interactions
through residues Arg42 and Glu43. A hydrophobic interface between
symmetry-related dimers arises primarily between switches 2 of
EhRacC and the α-helices of EhPAK4 PBD, burying ∼9500 Å2 of
surface area. Each of the four EhRacC/EhPAK4 dimers in the
asymmetric unit shares a similar interface with a symmetry-related
dimer. (C) Charge reversal at the crystal contact site (EhPAKR42D)
does not significantly alter the affinity for EhRacC·GTP as measured
by SPR. Equilibrium binding affinity constants are reported with the
standard error of the mean.
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particularly at the Rho GTPase/PBD interface, is potentially a




Tables of sequence identities for E. histolytica Rho GTPases and
p21-activated kinases. This material is available free of charge
via the Internet at http://pubs.acs.org.
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